

# Pharmacokinetic Boosting of Atazanavir with the Pharmacoenhancer GS-9350 versus Ritonavir

Reported by Jules Levin  
ICAAC Sept 11-15 2009 San Francisco

S Ramanathan, D Warren, L Wei, and BP Kearney  
Gilead Sciences, Inc., Foster City, CA, USA

## AUTHOR CONCLUSIONS

ATV/GS-9350 300/150 mg provides bioequivalent ATV exposures to ATV/r

ATV/GS-9350 administration is safe and well tolerated

The pharmacoenhancer GS-9350 may be a suitable alternative to RTV for boosting of ATV

A fully enrolled Phase II clinical trial comparing ATV/GS-9350 300/150 mg versus ATV/r 300/100 mg, each in combination with emtricitabine/tenofovir disoproxil fumarate, in treatment-naive HIV patients is ongoing

## INTRODUCTION

GS-9350 is a specific, potent, mechanism-based inhibitor of human cytochrome P450 3A (CYP3A) enzymes without antiviral activity

GS-9350 increases (boosts) plasma exposures of the CYP3A4 probe midazolam and the HIV integrase inhibitor elvitegravir comparably to ritonavir (RTV)<sup>1</sup>

Boosted-atazanavir (ATV) is an HIV protease inhibitor preferred for first line treatment of patients in HIV treatment guidelines

## BACKGROUND

ATV is a substrate and inhibitor of CYP3A4 and is coadministered with RTV, a CYP3A4 inhibitor, (ATV/r) to achieve high trough concentrations

ATV-associated adverse effects include hyperbilirubinemia due to UGT1A1 inhibition and modest PR interval prolongation

RTV-associated safety and tolerability issues include hyperlipidemia, gastrointestinal disorders, and risk for developing cardiac conduction

abnormalities2-4


GS-9350 may offer an alternative to RTV to boost ATV with the potential for reduced adverse biochemical effects

## Objectives

- To evaluate the pharmacokinetics of ATV when coadministered with GS-9350 or RTV
- To evaluate the safety of administration of ATV in combination with GS-9350 or RTV

## Methods

Figure 1. Study Design



- All treatments administered with a standard meal (~ 400 kcal, 13 g fat)
- Plasma PK sampling performed over 24 hours; ATV, GS-9350, and RTV levels determined using validated LC/MS/MS assays
- PK parameters estimated via non-compartmental methods using WinNonlin™ 5.2 (Pharsight Corporation, Mountain View, CA, USA)
- ANOVA and 90% confidence interval bounds for equivalence about the geometric mean ratio (Test:Reference) were 80 to 125% for ATV  $C_{max}$ ,  $AUC_{tau}$ , and  $C_{tau}$
- Descriptive PK for GS-9350 and RTV
- Adverse event (AE) monitoring, clinical laboratory and ECG evaluations performed throughout study

## Results


### Demographics

- 42 healthy subjects enrolled
  - 28 males, 14 females
  - Mean age: 28 yrs (range: 18 – 45)
  - Ethnicity: 28 White, 10 Black, 3 Asian, 1 Native American

### Disposition

- 33 completed study
- 9 discontinuations
  - 2 withdrew consent
  - 2 Investigator's discretion
  - 5 due to AEs

**Figure 2. ATV Plasma Concentration-Time Profile (mean  $\pm$  SD)**



**Table 1. Plasma Pharmacokinetic Parameters of ATV Following ATV/r 300/100 mg and ATV/GS-9350 300/150 mg Dosing**

ATV PK	ATV/GS-9350 300/150 mg (N = 34)	ATV/r 300/100 mg (N = 36)	GMR (90% CI)
AUC <sub>tau</sub> (ng·h/mL)	55,900 (28.2)	55,200 (27.6)	101 (94.5, 108)
C <sub>max</sub> (ng/mL)	4880 (24.9)	5270 (23.6)	92.3 (85.1, 100)
C <sub>tau</sub> (ng/mL)	1330 (42.7)	1340 (40.8)	97.6 (88.1, 108)
T <sub>½</sub> (h)	16.7 (11.7, 20.4)	15.7 (13.6, 21.1)	NA
T <sub>max</sub> (h)	3.0 (2.5, 3.5)	3.0 (2.5, 3.5)	NA

Data expressed as arithmetic mean (%CV) or \*median (Q1,Q3)  
 GMR: Geometric Mean Ratio; CI: Confidence Interval; NA : Not applicable

**Table 2. Plasma Pharmacokinetic Parameters of ATV Following ATV/r 300/100 mg and ATV/GS-9350 300/100 mg Dosing**

<b>ATV PK</b>	<b>ATV/GS-9350 300/100 mg (N = 35)</b>	<b>ATV/r 300/100 mg (N = 36)</b>	<b>GMR (90% CI)</b>
AUC <sub>tau</sub> (ng•h/mL)	45,100 (30.9)	55,200 (27.6)	81.2 (76.0, 86.7)
C <sub>max</sub> (ng/mL)	4420 (21.4)	5270 (23.6)	84.2 (77.7, 91.2)
C <sub>tau</sub> (ng/mL)	837 (58.8)	1340 (40.8)	57.4 (51.9, 63.5)
T <sub>½</sub> (h)	9.7 (7.1, 12.9)	15.7 (13.6, 21.1)	NA
T <sub>max</sub> (h)	3.5 (3.0, 4.0)	3.0 (2.5, 3.5)	NA

Data expressed as arithmetic mean (%CV) or \*median (Q1,Q3)

GMR: Geometric Mean Ratio; CI: Confidence Interval; NA : Not applicable

**Table 3. Plasma Pharmacokinetic Parameters of RTV and GS-9350 Following ATV/r and ATV/GS-9350 Dosing**

<b>PK Parameter</b>	<b>RTV</b>	<b>GS-9350</b>	
	<b>ATV/r 300/100 mg (N = 37)</b>	<b>ATV/GS-9350 300/150 mg (N = 35)</b>	<b>ATV/GS-9350 300/100 mg (N = 38)</b>
AUC <sub>tau</sub> (ng•h/mL)	11,900 (32.6)	11,300 (24.4)	5960 (23.3)
C <sub>max</sub> (ng/mL)	2050 (28.5)	1380 (19.3)	849 (18.1)
C <sub>tau</sub> (ng/mL)	74.4 (58.8)	61.6 (93.5)	21.7 (95.9)
T <sub>½</sub> (h)	5.3 (4.4, 6.1)	4.4 (3.5, 4.9)	4.1 (3.5, 4.6)
T <sub>max</sub> (h)	5.0 (4.5, 5.0)	3.0 (2.5, 3.5)	3.0 (2.5, 3.5)

Data expressed as arithmetic mean (%CV) or \*median (Q1,Q3)

## Pharmacokinetics

- Bioequivalent ATV exposures between ATV/GS-9350 300/150 mg and ATV/r 300/100 mg
  - Comparable  $T_{1/2}$  and  $T_{max}$  for these ATV treatments
- ATV/GS-9350 300/100 mg provided lower ATV exposures
- GS-9350 exposure increased greater than dose-proportional between 100 mg and 150 mg doses
- RTV pharmacokinetics comparable to historical data<sup>5</sup>

## Safety: Adverse Events (AEs)

- No Grade 3/4 AEs, serious AEs
- Discontinuations due to AEs (moderate (Grade 2) severity)
  - ATV/r: 2 (1 each for anemia, parasthesia)
  - ATV/GS-9350: rash (n = 2 at 100 mg, n = 1 at 150 mg GS-9350)
    - Resolved upon study drug discontinuation
- ATV/r and ATV/GS-9350 dosing generally well tolerated
  - Similar incidence of AEs across GS-9350 vs RTV treatments
  - Most frequent AEs: headache, ocular icterus, jaundice, contact dermatitis
  - AEs were mild or moderate and resolved on treatment

## Safety: Laboratory Abnormalities

### Liver: Table 4. Total Bilirubin

Treatment	Change from baseline (mean $\pm$ SD); mg/dL	Grade 3	Grade 4
ATV/GS-9350 300/100 mg	3.1 $\pm$ 1.9	30.0%	12.5%
ATV/GS-9350 300/150 mg	4.1 $\pm$ 1.5	57.9%	5.3%
ATV/r 300/100 mg	4.2 $\pm$ 1.7	52.6%	10.5%

- Total bilirubin returned to baseline levels upon washout ( $\sim$ 0.5 mg/dL)
- No changes in ALT, AST, GGT

## ECG

- No clinically relevant changes in QTcF, QRS intervals
- No difference in PR interval changes for ATV/GS-9350 vs ATV/r ( $p > 0.05$ )
  - Maximum change from baseline (mean  $\pm$  SD)
    - ATV/GS-9350 300/100 mg: 19.2  $\pm$  16.2 msec
    - ATV/GS-9350 300/150 mg: 22.3  $\pm$  17.2 msec
    - ATV/r 300/100 mg: 15.9  $\pm$  12.6 msec
    - Historical data - ATV/r 300/100 mg: 20  $\pm$  42 msec<sup>6</sup>;  
ATV 400 mg: 24  $\pm$  15 msec<sup>7</sup>
  - Three subjects had Grade 1 PR interval prolongation during all three treatments

## REFERENCES

1. Mathias, A et al. GS-9350: A pharmacoenhancer without antiviral activity. 16<sup>th</sup> Conference on Retrovirus and Opportunistic Infections, 2009 Montreal, CA
2. Shafran, SD et al. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. *HIV Medicine* (2005) 6:6, 421-425
3. Collot-Teixeira, S et al. Impact of Different Low-Dose Ritonavir Regimens on Lipids, CD36, and Adipophilin Expression. *Clin. Pharmacol. Ther.* (2009) 85:4, 375-378
4. Norvir, US Prescribing Information, October 2008.
5. Agarwala, S et al. Pharmacokinetic (PK) effect of Omeprazole (OMP) on

atazanavir (ATV) with ritonavir (RTV) in healthy subjects [poster #658].  
12<sup>th</sup> Conference on Retroviruses and Opportunistic Infections 2005,  
Boston, MA.

6. Zhu, L et al. Pharmacokinetics, safety and tolerability of atazanavir 200,  
300, and 400 mg twice-daily in healthy subjects [poster #A-952]. 48<sup>th</sup>  
Annual ICAAC/IDSA Meeting 2008, Washington, DC.

7. Reyataz US Prescribing Information, April 2009.